2024/12/03 by Stephanie Franco, Lucy A. Godley · 1 voice
Medicine · #Acute Lymphoblastic Leukemia research #Acute Myeloid Leukemia Research #Myeloproliferative Neoplasms: Diagnosis and Treatment
paper · pdf · doi:10.1084/jem.20230931
openalex publication_date 2024/12/03 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
Somatic variants accumulate in all organs with age, with a positive selection of clonal populations that provide a fitness advantage during times of heightened cellular stress leading to clonal expansion. Easily measured within the hematopoietic compartment, clonal hematopoiesis (CH) is now recognized as a common process in which hematopoietic clones with somatic variants associated with hematopoietic neoplasms exist within the blood or bone marrow of individuals without evidence of malignancy. Most cases of CH involve a limited number of genes, most commonly DNMT3A, TET2, and ASXL1. CH confers risk for solid and hematopoietic malignancies as well as cardiovascular and numerous inflammatory diseases and offers opportunities for cancer prevention. Here, we explore the genetic and environmental factors that predispose individuals to CH with unique variant signatures and discuss how CH drives cancer progression with the goals of improving individual cancer risk stratification, identifying key intervention opportunities, and understanding how CH impacts therapeutic strategies and outcomes.